Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy
Ovarian Neoplasms
About this trial
This is an interventional treatment trial for Ovarian Neoplasms focused on measuring Müllerian Carcinoma, Doxil, Japanese Patients
Eligibility Criteria
Inclusion Criteria: Patients with ovarian cancer who had a response to initial treatment but then relapsed within 12 months are eligible Patients with ovarian cancer who have received one or two prior chemotherapy treatment are eligible Patients must have measurable disease, good performance status and adequate major organ function Exclusion Criteria: Patients with concomitant disease that may affect the conduct of the study and the evaluation of pegylated liposomal doxorubicin hydrochloride Patients with systemic infection Patients with active second cancer besides the ovarian cancer Patients with pleural effusion or ascites requiring continuous drainage at the time of enrollment Patients with pericardial fluid requiring drainage Patients with myocardial infarction and/or angina attack within 90 days prior to enrollment.